Rx Reconcile 32 mg x 30 tablets

Reconcile Reconcile tablets are used to help your canine cope with seperation anxiety. Reconcile not only helps your pet stay calm during stressful moments of being apart, but it can also help reduce behavior that may be harmful and open more to training. Flavored chewable tablets that are formulated with fluoxetine hydrochloride for the treatment of canine seperation anxiety when combined with a behavior modification plan. Prescription items are NON-RETURNABLE and NON-REFUNDABLE. - CAUTIONS/WARNINGS:Contraindications RECONCILE chewable tablets are contraindicated for use in dogs with epilepsy or a history of seizures. RECONCILE chewable tablets should not be given concomitantly with drugs that lower the seizure threshold (e.g., phenothiazines such as acepromazine or chlorpromazine). RECONCILE chewable tablets should not be given in combination with a monoamine oxidase inhibitor (MAOI) [e.g., selegiline hydrochloride (L-deprenyl) or amitraz], or within a minimum of 14 days of discontinuing therapy with an MAOI. RECONCILE chewable tablets are contraindicated in dogs with a known hypersensitivity to fluoxetine HCl or other SSRIs. Because fluoxetine and its major metabolite, norfluoxetine, have long half-lives, a 6-week washout interval should be observed following discontinuation of therapy with RECONCILE chewable tablets prior to the administration of any drug that may adversely interact with fluoxetine or norfluoxetine. Human Warnings Not for use in humans. Keep out of reach of children. In case of accidental ingestion seek medical attention immediately. In humans, the most common symptoms associated with over dosage include seizures, somnolence, nausea, tachycardia, and vomiting. In case of ingestion by a human, contact a physician immediately. For a copy of the Material Safety Data Sheet (MSDS) or to report adverse reactions call 1-888-545-5973. Precautions RECONCILE chewable tablets are not recommended for the treatment of aggression. RECONCILE chewable tablets have not been clinically tested for the treatment of other behavioral disorders. Studies to determine the effects of RECONCILE chewable tablets in breeding, pregnant, or lactating dogs and in patients less than 6 months of age have not been conducted. Seizures may occur in dogs treated with RECONCILE chewable tablets, even in dogs without a history of epilepsy or seizures (see ADVERSE REACTIONS). Before prescribing RECONCILE chewable tablets, a comprehensive physical examination should be conducted to rule out causes of inappropriate behavior unrelated to separation anxiety. The examination should include a thorough history and assessment of the patient’s household environment and standard practice laboratory tests as appropriate for the patient’s age and health status. Veterinarians should be familiar with the risks and benefits of the treatment of behavioral disorders in dogs before initiating therapy. Inappropriate use of RECONCILE chewable tablets, i.e. in the absence of a diagnosis or without concurrent behavior modification, may expose the animal to unnecessary adverse reactions and may not provide any lasting benefit of therapy. RECONCILE chewable tablets have not been evaluated with drugs that affect the cytochrome P450 enzyme system. RECONCILE chewable tablets should be used with caution when co-administered with any drug that affects the cytochrome P450 enzyme system (for example, ketoconazole). Studies to assess the interaction of RECONCILE chewable tablets with tricyclic antidepressants (TCAs) (for example, amitriptyline and clomipramine) have not been conducted. The minimum washout period to transition dogs from TCAs to RECONCILE chewable tablets has not been evaluated. Published pharmacokinetic data demonstrates that TCAs are cleared 4 days following discontinuation. 1,2 Storage Information Store at 20-25°C (68-77°F). Excursions permitted between 15-30°C (59-86°F). Do not remove desiccant canister from the bottle. Completely close bottle between uses. - DIRECTIONS:Reconcile Dosage And Administration The recommended dose of RECONCILE chewable tablets is 1-2 mg/kg (0.5-0.9 mg/lb) administered once daily, in conjunction with a behavior modification plan. A typical behavior modification plan consists of the pet owner implementing standard training techniques based on principles such as rewarding appropriate behavior; coming and going in a manner that does not elicit inappropriate responses from the dog; and teaching the dog to be content while alone. Dogs: 8.8-17.6 lbs - Give one 8mg chewable tablet once a day 17.7-35.2 lbs - Give one 16mg chewable tablet once a day 35.3-70.4 lbs - Give one 32mg chewable tablet once a day 70.5-140.8 lbs - Give one 64mg chewable tablet once a day Professional judgment should be used in monitoring the patient's response to therapy to determine the need to continue treatment with RECONCILE chewable tablets beyond 8 weeks. To discontinue therapy, it is not necessary to taper or reduce doses because of the long half-life of this product. Continued behavioral modification is recommended to prevent recurrence of the clinical signs. RECONCILE chewable tablets are readily consumed by dogs or can be administered like other tablet medications, and can be given with or without food. If a dose is missed, the next scheduled dose should be administered as prescribed. Do not increase or double the dose. - HEIGHT(INCHES): 3.500 - WIDTH(INCHES):1.900 - LENGTH(INCHES):1.900